이코티닙(Icotinib) 시장 규모, 점유율, 성장 분석 : 제품 유형별, 적응증별, 제형별, 치료 라인별, 최종사용자별, 유통 채널별, 지역별 - 업계 예측(2026-2033년)

Global Icotinib Market size was valued at USD 782.5 Million in 2024 and is poised to grow from USD 852.93 Million in 2025 to USD 1699.51 Million by 2033, growing at a CAGR of 9.0% during the forecast period (2026-2033).

The global icotinib market is primarily driven by its targeted EGFR inhibition and competitive pricing, leading to widespread adoption in China and Asia. As an oral tyrosine kinase inhibitor for EGFR-mutant non-small cell lung cancer, icotinib benefits from a dynamic landscape influenced by branded and generic products, clinical guidelines, and regulatory decisions. Its efficacy in improving progression-free survival at a lower cost compared to alternatives has encouraged insurers and hospitals to incorporate it into treatment options. Furthermore, advancements in molecular diagnostics are enhancing the identification of EGFR mutations, thereby expanding the patient pool. The inclusion of icotinib in hospital formularies is improving patient access, while the rise of generics and AI technologies streamlines patient selection and optimizes treatment outcomes, driving market growth.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Icotinib market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Icotinib Market Segments Analysis

Global icotinib market is segmented by product type, indication, dosage form, treatment line, end-user, distribution channel and region. Based on product type, the market is segmented into Branded Icotinib and Generic Icotinib. Based on indication, the market is segmented into Non-Small Cell Lung Cancer (NSCLC) and Other Oncology Indications. Based on dosage form, the market is segmented into Oral Tablets and Other Formulations. Based on treatment line, the market is segmented into First-Line Therapy and Second-Line / Later-Line Therapy. Based on end-user, the market is segmented into Hospitals, Oncology Clinics, Retail Pharmacies, Online Pharmacies and Diagnostic & Research Centers. Based on distribution channel, the market is segmented into Direct Manufacturer Sales, Distributors & Dealers and Online Pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Icotinib Market

The global icotinib market is significantly propelled by its integration into treatment protocols for EGFR-mutated non-small cell lung cancer, along with its commendation among healthcare professionals for its oral administration and favorable safety profile. The predictability of its tolerability fosters confidence in long-term treatment, enhancing patient adherence and encouraging clinicians to incorporate icotinib early in therapeutic sequences. This growing clinical acceptance bolsters its adoption within hospital formularies and outpatient settings, motivating manufacturers to increase supply and awareness. Ultimately, these factors contribute to the broader expansion of the market, fueled by provider support and consistent prescribing practices.

Restraints in the Global Icotinib Market

The global icotinib market faces significant challenges due to restrictive reimbursement policies and varying coverage decisions among payers, which hinder patient access by introducing uncertainty regarding affordability and out-of-pocket expenses. Limited coverage options or the necessity for prior authorization place an additional administrative burden on clinicians, who may then choose alternative therapies with more straightforward funding processes. This situation diminishes prescribing enthusiasm and lessens the motivation for healthcare facilities to keep the drug readily available. Consequently, this inconsistency in access discourages widespread adoption, complicates market penetration strategies, and diminishes the reliable demand that manufacturers need to support their expansion efforts.

Market Trends of the Global Icotinib Market

The Global Icotinib market is currently witnessing a significant trend towards targeted therapies that cater to molecularly defined patient segments. This shift has prompted pharmaceutical developers to concentrate on precision dosing and the integration of companion diagnostics, fostering personalized treatment pathways. Market participants are focusing on establishing differentiated profiles that highlight unique safety and efficacy narratives, while healthcare payers and clinicians demand clear value propositions linked to real-world outcomes. Consequently, this trend underpins lifecycle strategies that align clinical positioning with diagnostic collaborations, enhancing predictable adoption within specific indications and fostering placements in therapeutic algorithms through robust evidence-based strategies and stakeholder engagement.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Icotinib Market Size by Product Type & CAGR (2026-2033)

• Market Overview
• Branded Icotinib
• Generic Icotinib

Global Icotinib Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Non-Small Cell Lung Cancer (NSCLC)
• Other Oncology Indications

Global Icotinib Market Size by Dosage Form & CAGR (2026-2033)

• Market Overview
• Oral Tablets
• Other Formulations

Global Icotinib Market Size by Treatment Line & CAGR (2026-2033)

• Market Overview
• First-Line Therapy
• Second-Line / Later-Line Therapy

Global Icotinib Market Size by End-User & CAGR (2026-2033)

• Market Overview
• Hospitals
• Oncology Clinics
• Retail Pharmacies
• Online Pharmacies
• Diagnostic & Research Centers

Global Icotinib Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Direct Manufacturer Sales
• Distributors & Dealers
• Online Pharmacies

Global Icotinib Market Size & CAGR (2026-2033)

• North America (Product Type, Indication, Dosage Form, Treatment Line, End-User, Distribution Channel)
  • US
  • Canada
• Europe (Product Type, Indication, Dosage Form, Treatment Line, End-User, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Product Type, Indication, Dosage Form, Treatment Line, End-User, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Product Type, Indication, Dosage Form, Treatment Line, End-User, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product Type, Indication, Dosage Form, Treatment Line, End-User, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Jiangsu Hengrui Medicine Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zhejiang Haiyuan Pharmaceutical Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BeiGene, Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sinopharm Group Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Shanghai Fosun Pharmaceutical Group Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Chugai Pharmaceutical Co., Ltd.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca PLC
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Merck & Co., Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Holding AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amgen Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Takeda Pharmaceutical Company Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AbbVie Inc.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Celgene Corporation
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GSK plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Boehringer Ingelheim GmbH
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A.
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations